Introduction
============

"Anorexia nervosa is a psychiatric disorder characterized by fear of weight gain and dangerously low body weight ... mortality rate exceeds that of other psychiatric disorders ... finding comprehensive brain-based models ... has been difficult\" ([@B36]). Thus start most accounts. But it was recently suggested that this standard perspective needs to be modified because the treatment of anorexia is at a standstill ([@B44]). We will describe the standard perspective and its translation into clinical practice first and then we will describe the evolutionary perspective, with eating behavior in clinical practice.

The Standard Perspective
========================

On the standard perspective, anorexia is caused by a pre-existing, neurochemically mediated, genetically determined mental disorder as outlined some time ago as: "We hypothesize that people with anorexia nervosa have a trait-related *increase* in 5-HT neuronal transmission that occurs in the premorbid state and persists after recovery" ([@B50]) and: "Childhood anxiety represents one important genetically mediated pathway toward the development of anorexia nervosa and bulimia nervosa" ([@B51]). The perspective is similar today ([@B90]).

Clinical Translation of Neurochemistry and Genetics
---------------------------------------------------

If anorexia is caused by an increase of 5-HT synthesis an inhibitor or an antagonist should be used, but paradoxically, indirect agonists are used, and although useful in patients with mental disorders ([@B61]), these drugs are not useful in patients with anorexia ([@B92]; [@B100]). But neither are other drugs, including neuroleptics, which are valuable for patients with mental disorders ([@B60]), useful in patients with eating disorders ([@B3]). This differential effectiveness of psychopharmacological intervention may be because the "mental disorders" of eating disorders differ from those of patients with mental disorders. Thus, a rating scale that dissociates anxiety from other mental disorders in patients with mental disorders did not dissociate these disorders in 358 patients with anorexia nervosa \[PS and others, manuscript submitted for [@B44]\].

The discovery that mental disorders are not distinct categories but vary along continuous dimensions was made long ago ([@B35]; [@B68]), emphasized not long ago ([@B12]) and recently re-discovered ([@B15]; [@B67]; [@B75]). Hence, attempts to find genotype-phenotype correlations among eating disorders and mental disorders have yielded inconsistent results ([@B12]). Translating these results into treatments for eating disorders will be difficult ([@B16]). This approach, which was launched 20 years ago in other contexts, has been marginally successful ([@B48]).

The Standard Treatment
----------------------

The standard treatment, cognitive behavioral therapy (CBT), assumes that eating disorders are maintained by cognitive processes. Even though CBT does not address the cause of eating disorders, it recognizes that the patients' problems start with dieting ([@B79]). Launched for bulimia nervosa in 1981 ([@B32]), CBT is now recommended in the treatment guidelines for all eating disorders throughout the world \[e.g., ([@B65])\].

Rather few patients have been treated with CBT in randomized controlled trials (RCT) ([@B79]). With a dropout rate ≈30%, which is generally expected and included in the power calculations of RCTs ([@B101]), a rate of remission \<50% and a rate of relapse ≥30% within 1 year, ≤25% of the patients remain in remission at this point in time ([@B82]).

Many more patients have been treated with CBT in general practice. For example, out of 683 patients referred to primary care for the treatment of bulimia within the United Kingdom healthcare system, 135 completed the treatment but although they improved, these patients did not remit ([@B54]). In Sweden, 15,411 patients were similarly treated in years 2012--2017 with a rate of remission of 18.4% at one year follow-up ([@B11]). There are no major differences between these outcomes and the outcomes in the specialized clinics in Sweden and other countries ([@B82], [@B86]).

What explains these low remission rates? Consider the most recent RCT in which 15 out of 36 patients (42%) went into remission from bulimia but not from anxiety ([@B69]). On the standard perspective, anxiety causes bulimia ([@B51]) and it is unsurprising, therefore, that 5 of the 15 patients (33%) relapsed within 19 months. A new review found no "relevant new RCTs" and concluded that CBT is "an effective approach" ([@B79]), despite the fact that 22.2% of the patients dropped out, 33% relapsed and 39.3% received additional treatment during follow-up in the trial ([@B69]). Considering that there is no information of long-term outcomes, it should be possible to improve the effectiveness of CBT ([@B82]; [@B79]). A new perspective might offer a start.

The Evolutionary Perspective
============================

A framework for anorexia nervosa, the prototypical eating disorder from which the other eating disorders emerge, was launched in 1996, with food restriction as the main cause ([@B9]). The neuroendocrine changes associated with this brain-based model have been reviewed ([@B6], [@B7]; [@B100]; [@B87], [@B83], [@B82]) and can be briefly updated as follows.

Because starvation has been the main threat in evolution it is fitting to paraphrase Dobzhansky: "Nothing in the biology of anorexia makes sense except in the light of evolution" ([@B28]). And 36 years ago, it was realized that the conspicuous high physical activity of anorexia is a normal, evolutionary conserved response, i.e., foraging for food when food is in short supply ([@B29]). Later on, the evolutionary perspective was presented twice more ([@B43]; [@B87]).

In fact, anorexia provides an example of the human homeostatic phenotype, as this concept emerged from the clinical observations and hypotheses of Bernard and the subsequent experimental verifications of Cannon ([@B87]). This perspective has now been validated for brain function. Thus, the signaling molecules of the hypothalamic arcuate nucleus support the search for food, rather than eating ([@B2]; [@B64]; [@B22]; [@B27]; [@B19]). The agouti-related protein neurons of this nucleus can monitor the availability of food in the environment, changing energy utilization from fat to carbohydrate ([@B22]; [@B18]; [@B21]). Silencing these neurons eliminates the search for food but leaves chewing and swallowing unaffected ([@B89]), replicating the effect of dopamine receptor blockade or depletion ([@B10]; [@B5]; [@B71]).

The search for food and eating behavior, chewing in particular, have dominated the evolution of the behavior and the anatomy of the individual, including the head and the brain ([@B58], [@B59]; [@B91]; [@B80]). "You are How you eat," suggests the evolutionary biologist and even that we should "encourage \[our children\] to chew more gum" ([@B58]). And since it was first reported that chewing gum is relaxing 80 years ago ([@B45]), it is now recognized that chewing gum promotes both physical and mental health ([@B38]). The neural engagement in these beneficial effects of chewing include the serotonin cells in the dorsal raphe nucleus in the brainstem and their projections to the prefrontal and orbitofrontal cortex ([@B46]). These serotonin neurons and the hypothalamic agouti-related protein neurons also activate dopamine neurons in the ventral tegmental area in the brainstem ([@B26]; [@B17]). Interestingly, activity in these mesolimbic dopamine neurons can functionally rearrange the connections within the prefrontal cortex ([@B49]). Foraging for food has shaped these cortical and subcortical areas into an extended neural network, parts of which are differentially engaged dependent upon environmental conditions ([@B55]; [@B66]; [@B20]; [@B56]). Dopamine, of course, plays roles in addition to the one(s) discussed here, some of which are important in evolution, including the management of threats ([@B63]).

It is well known that in evolution "men hunt and women gather" ([@B34]; [@B42]), but it is not yet known how these behavioral sex differences are related to the neural network of foraging. Research on the neuroscience of foraging often use economic rewards and choices, food rewards are less common ([@B55]; [@B77]). However, it was observed long ago that the emergence of the prefrontal cortex in primate evolution coincided with improvement of the strategies for food foraging (overview in [@B40]). Gonadal hormone sensitive sex differences have since been demonstrated in the anatomy of the prefrontal cortex and these can be related to sexually dimorphic behavior ([@B23]; [@B31]). On the evolutionary perspective, it is tempting, therefore, to speculate that these findings are related to the marked sex difference in the prevalence of anorexia nervosa.

The neurobehavioral responses to food deprivation and the corresponding genotype are evolutionarily conserved and consistent with the evolutionary perspective of anorexia nervosa ([@B87]; [@B1]; [@B47]; [@B41]; [@B74]).

The Elusive Clinical Translation of the Neurobiology of Foraging
----------------------------------------------------------------

But rather than controlling behavior, the neural network just outlined is permissive; the cause of changes in eating behavior is outside of the individual ([@B85]; [@B96]). For example, the behavioral effects of experimental activation of the brainstem to prefrontal cortex part of the network in one environment are the opposite to the behavioral effect of the same experimental maneuver in another environment ([@B93]; [@B76]). Similarly, stimulating the brain with neuropeptide tyrosine makes a rat eat more food when food is continuously available but makes the rat forage for food and eat less food when the availability of food is restricted ([@B2]; [@B64]). These results support the proposed causal role of the environment in body weight regulation and suggest that neuropharmacological intervention may remain ineffective.

In normal circumstances, our biological propensity to eat as much as possible is counterbalanced by the need to forage for food ([@B85]). But today the effort to find food is minimal and in the absence of internal controls people need external support in order not to lose control over body weight ([@B87]).

Eating Behavior in Treatment
----------------------------

In the clinic, we have therefore outsourced the control of eating behavior and body weight to a machine first described in 1996 ([@B8]; [@B81]). The patients learn to eat assisted by visual feedback from a computer screen as described many times already and recently in an open access video ([@B30]). But they are also treated with warmth, their physical activity is reduced and they are supported to resume their social activities ([@B6]). An RCT demonstrated the treatments effectiveness ([@B6]), which was confirmed by a description of the outcomes at 3 months intervals during treatment and 1, 2, 3, 6, 9, 12, 18, 24, 26, 48, and 60 months after remission in 1,428 patients treated in six clinics in four countries ([@B7]). The rate of remission was estimated to 75% within on average 1 year of treatment and the rate of relapse was estimated to 10% ([@B7]). Psychoactive drugs that had been prescribed prior to admission to treat mental symptoms were withdrawn while the patients remitted from these symptoms by re-learning how to eat (PS and others, manuscript submitted for [@B44]).

The Paradox of Standard Treatment
=================================

More patients go into remission in the long-term by re-learning how to eat than if treated with CBT ([@B82], [@B86]). The difference in outcome is unlikely due to difference in the state of the patients at admission. The published literature suggests the opposite; patients who are treated with standards of care are less serious ill at admission than patients whose eating behavior is treated ([@B83]).

Considering the difference in outcomes, it is paradoxical that "the single most effective procedure in CBT" has long been recognized as "*the prescription of a pattern of regular eating"* ([@B33]). But because is unclear how this is achieved we have invited CBT-clinicians to use our method for treating eating behavior ([@B82]).

How to Eat
==========

The biological, default pattern of eating behavior, a gradual decrease in the rate of eating over the course of a meal, was first described in experimental animals as: N = Kt^n^; where N = amount of food eaten at time t and K and n are constants ([@B78]) and then modified as an exponential growth curve: f = c(l-e^-mt^); where f = amount of food eaten, c and m constants and t = time ([@B13]). A model of human eating behavior was presented as: y = kx^2^+lx; where y = amount of food eaten, k = change in the rate of eating over the course of the meal and l = initial rate of eating ([@B70]). This model was subsequently confirmed ([@B53]). The recent suggestion that the model should predict outcomes and disclose mechanisms is based on 40 year old experimental results rather than the recent biology of foraging ([@B88]). At present, the model remains descriptive, but as outlined here, it can be used in the treatment of eating behavior in patients with eating disorders.

With *k* \< 0 in the model, Westerterp-Plantenga launched the term decelerated eating and with k≈0, she launched the term linear eating ([@B94]). If rats are deprived of food for 4 days, food intake decreases the linearity of eating increases ([@B14]). Women respond in the same manner after merely skipping dinner ([@B57]; [@B99]).

Linear eaters eat less food yet feel increasingly full when eating at a reduced rate experimentally and they eat more food yet feel less full when eating at an increased rate experimentally ([@B97]). Thus, dieting, the main cause of anorexia, causes linear eating very rapidly and puts women at risk of losing control over food intake. These undesirable effects can be prevented by practicing eating at a decelerated rate ([@B98]). And when women transit from linear eating to decelerated eating their mental state normalizes ([@B98]), just as 737 patients remitted from their mental symptoms by re-learning how to eat ([@B7]).

The Eating Behavior of Anorexic Patients Treated to Remission
=============================================================

The derivative of the old model is a line but growth, including cumulative food intake, tapers off. We therefore re-launch the two-parameter asymptotic exponential curve as a minimally redundant model of eating behavior: y = a(1-e^-bt^), where y = amount of food eaten, a = hypothetical maximal food intake, b = change in the rate of eating and t = time ([@B13]).

Using non-linear regression ([@B4]; [@B72]), we describe the eating behavior of 17 women who were treated to remission from anorexia nervosa by practicing how to eat. Their mean (SD) age was 18.8 (3.7) years, they had been ill for 3.3 (2.2) years and had a Body Mass Index, BMI = 14.9 (1.0) at admission. The women went into remission in 359 (78) days, at a BMI = 19.8 (0.9). For a complete list of remission criteria, see ([@B6]). Their eating behavior was compared to that of 17 healthy women, who were 23.6 (2.0) years old and had a BMI = 23.5 (1.5). The choice of 5 years older healthy women for comparison was based on the fact that patients who have been treated to remission are followed up for 5 years before they are considered cured ([@B6]).

**[Table 1](#T1){ref-type="table"}** shows that the patients ate only little food, slowly, at admission, but when in remission, they ate somewhat more food than the healthy women and the duration of their meal was a little shorter. While the initial rate of eating among the anorexics in remission and the healthy women was similar, the rate of eating decreased over the course of the meal significantly more among the healthy women than among the women in remission. These differences in eating behavior emerge clearly in **[Figure 1](#F1){ref-type="fig"}**. One of the patients continued eating for 37 min at admission, i.e., beyond the 20 min limit displayed (bottom graph in panel A). Three patients ate in a linear manner at remission and their curves are therefore omitted in panel B.

###### 

Food intake, meal duration, initial rate of eating, change in rate of eating over the course of the meal (b) and hypothetical maximal food intake (a) in 17 women at admission for the treatment of Anorexia Nervosa (Adm AN) and at remission after treatment (Rem AN) and in 17 healthy women (Healthy).

  Group     Food intake (g)     Meal duration (min)   Initial rate of eating (g/min)^a^   Change in rate of eating (b)   Hypothetical maximal food intake (a)
  --------- ------------------- --------------------- ----------------------------------- ------------------------------ --------------------------------------
  Adm AN    100 (72--160)^b^    10.4 (7.7--13.6)      8.4 (6.2--16.3)^b^                  --                             
  Rem AN    307 (266--351)^c^   9.6 (8.0--10.6)^c^    44.3 (34.4--46.9)                   0.06 (0--0.22)^d^              586 (377--684)
  Healthy   268 (208--389)      10.7 (10.1--12.2)     39.1 (35.8--46.9)                   0.12 (0.05--0.23)              374 (333--444)

Values are median (quartile range). See text for model of eating behavior.
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![Change in the rate of eating in 17 women at admission **(A)** and at remission **(B)** after treatment of anorexia nervosa and in 17 healthy women **(C)**. Data in **A** are raw data collected at 1 min intervals. Data in **B,C** are modeled by a two-parameter asymptotic exponential curve, see text for details.](fnins-13-00596-g001){#F1}

Comments, Personal Insights and Opinions
========================================

While the anorexic women who practiced eating reached a BMI within the normal range and consumed a normal amount of food, their weight and their eating behavior was not the same as those of the healthy women. Our patients are followed for 5 years after treatment, including eleven appointments ([@B6], [@B7]) and, at present, we are examining if their physical characteristics and their eating behavior more closely resembles those of healthy women once they have completed the follow-up program. Yet, at the present state of knowledge, it is reasonable to suggest that patients with eating disorders should be offered the chance to practice eating using the device that has now restored the physical and mental health of hundreds of patients ([@B7]; [@B82], [@B86]). Eating behavior thus treated makes it less important, albeit perhaps not unimportant, to treat cognitive processes ([@B82]), although evidence that these interventions are redundant was presented 31 years ago ([@B37]).

Practicing eating restores the levels of hormones thought to cause weight problems in obesity ([@B39]; [@B84]), suggesting eating behavior control of hormonal secretion, i.e., the opposite causal relationship to the conventional homeostatic relationship ([@B62]). The bidirectional relationship among brain and behavior, suggested by [@B25] and confirmed in recent years ([@B95]; [@B73]), provides support for clinical translation of the present perspective.

In 1996 we suggested that eating disorders are eating disorders, rather than mental disorders, and that the patients therefore should practice eating ([@B9]; [@B8]). At the time, it was thought that this was misplaced and even dangerous ([@B24]), but today, 23 years later, no-one can treat patients with eating disorders in the Region of Stockholm unless a program for restoring their eating behavior is included in the treatment. Such overly long delays before evidence-based interventions are introduced into clinical practice are common ([@B52]). Policies to shorten the delay would be useful.
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